Slayback’s Belrapzo Non-Infringement Judgement Is Upheld On Appeal
In Dispute Over Dedication-Disclosure Doctrine
Slayback Pharma has succeeded in defending itself on appeal that it did not infringe certain patents shielding Eagle Pharmaceuticals’ Belrapzo rapid-infusion bendamustine product, after a district court applied the dedication-disclosure doctrine to bar the originator’s claim.
You may also be interested in...
Teva has fought off US challenges from several of its generics peers over US patents protecting the Bendeka brand that the Israeli firm licenses from Eagle Pharmaceuticals.
Slayback Pharma and the Everstone Group have struck a deal that will see Everstone invest up to $50m in the US-based complex generics specialist.
Korean firm Celltrion is aiming to move production of insulin pens inside Korea “for the first time” and break the stranglehold of Big Pharma insulin players in the market by launching a biosimilar product in 2025.